Evidence map›Paper›PMID 30533584›Full record

ArticleACS omega2018

Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors.

Domna Iordanidou, Tryfon Zarganes-Tzitzikas, Constantinos G Neochoritis, Alexander Dömling, Ioannis N Lykakis

Abstract read
In one paragraph

Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Synthesis of Chromeno[3,4-Molecules (Basel, Switzerland) · 2021
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Domna IordanidouDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, Thessaloniki 54124, Greece.
Tryfon Zarganes-TzitzikasDepartment of Pharmacy, Drug Design Group, University of Groningen, A. Deusinglaan 1, Groningen 9713 AV, The Netherlands.
Constantinos G NeochoritisDepartment of Pharmacy, Drug Design Group, University of Groningen, A. Deusinglaan 1, Groningen 9713 AV, The Netherlands.
Alexander DömlingDepartment of Pharmacy, Drug Design Group, University of Groningen, A. Deusinglaan 1, Groningen 9713 AV, The Netherlands.
Ioannis N LykakisDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, Thessaloniki 54124, Greece.

Funding

Real-time discovery of inhibitors among billion compounds for preview and downloadR01GM097082 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAMACHO, CARLOS J. · 2011 to 2020
$2.5M
NIGMS NIH HHS R01 GM097082
6 · The paper itself

Abstract

The catalytic efficacy of silver nanoparticles was investigated toward the chemoselective reduction of nitro-tetrazole or amino acid-substituted derivatives into the corresponding amines in high isolated yields. This highly efficient protocol was thereafter applied toward the multicomponent reaction synthesis of heterocyclic dihydroquinoxalin-2-ones with high isolated yields. The reaction proceeds with low catalyst loading (0.8-1.4 mol %) and under mild catalytic conditions, a very good functional-group tolerance, and high yields and can be easily scaled up to more than 1 mmol of product. Thus, the present catalytic methodology highlights a useful synthetic application. Different molecules are designed and accordingly synthesized with the current protocol that could play the role of inhibitors of the soluble epoxide hydrolase, an important target for therapies against hypertension or inflammation.

Identifiers

PMID30533584
PMCPMC6276200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.